AstraZeneca has Sold more than $ 1 Billion worth of Vaccines
Pharmaceutical company AstraZeneca announced on Thursday that sales of its COVID-19 vaccine reached $ 1.17 billion in the first half of 2021. This amount corresponds to the delivery of around 319 million doses worldwide. , which the group sells at cost, without profit.
Sales represented $ 572 million in Europe and $ 455 million in emerging countries, according to a statement from the Swedish-British group.
Group sales over the period increased 23% year-on-year to $ 15.5 billion, and group share of net profit rose 40% to $ 2.1 billion. The pharmaceutical company also emphasizes that progress in its portfolio of developing products supports its growth in the longer term. The company is also raising its earnings forecast for the full year to reflect the contribution of the American biotechnology company Alexion, whose acquisition has just been finalized, but without taking into account sales of vaccines against the disease. COVID-19.
This is the number of doses of the COVID-19 vaccine that the group has sold around the world, at cost, without making a profit.
“AstraZeneca generated a new period of strong growth thanks to a solid performance in all regions and in all pathologies,” particularly in oncology, said Managing Director Pascal Soriot. “[The company] continues to recognize significant risks and uncertainties associated with the impact of COVID-19, including the potential impact of new anti-virus drugs currently in clinical development. ”
The development of AstraZeneca’s COVID-19 vaccine, although one of the very first on the market, while the group had not previously been very present in the vaccine sector, has been followed by many problems for the group, with particular doubts expressed about its effectiveness and concerns after rare cases of blood clots in view of the millions of doses administered. Added to this was a dispute with Brussels over vaccine deliveries.